BLUE - Bluebird Bio Inc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• First RSV shots, groundbreaking gene therapy among 2024 drugs to watch
• Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024
• CRISPR, bluebird stocks slide as Agios rallies on thalassemia study
• Another CRISPR approval not likely 'any time soon' - report
• Cell and gene therapy market to reach $80B by 2029: report
• bluebird bio stock slides on pricing of $125 million stock offering
• Biggest stock movers today: Enphase Energy, Affirm, bluebird bio, Plug Power and more
• bluebird bio announces proposed public offering of common stock
• bluebird bio gains on deal with commercial payer
• TD Cowen cuts CRISPR to underperform, cites "irrational" valuation
• bluebird bio gene therapy lovo-cel for sickle cell disease has $3.1M cost (updated)
• Morgan Stanley ups bluebird to equal weight ahead of FDA decision
• bluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02M
• bluebird bio Q3 2023 Earnings Preview
• Bluebird bio to sell FDA voucher for $103M if sickle cell disease therapy approved
• Bluebird stock falls 10% ahead of FDA meeting for rival sickle cell therapy
• HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead
• Bluebird bio favored at Baird as sickle cell disease space gets busy
• Vertex/CRISPR, bluebird sickle cell therapies could be cost-effective - ICER
• bluebird bio's lovo-cel won't have FDA advisory panel meeting